Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

AZD5991

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AstraZeneca

Drug class:

MCL1 inhibitor

Related drugs:

PRDX1 overexpression	Hepatocellular Cancer	PRDX1 overexpression	Hepatocellular Cancer	AZD5991 Sensitive: C3 – Early Trials AZD5991 Sensitive : C3	AZD5991 Sensitive: C3 – Early Trials AZD5991 Sensitive : C3
BCL2 overexpression	Acute Myelogenous Leukemia	BCL2 overexpression	Acute Myelogenous Leukemia	venetoclax + AZD5991 Sensitive: D – Preclinical venetoclax + AZD5991 Sensitive : D	venetoclax + AZD5991 Sensitive: D – Preclinical venetoclax + AZD5991 Sensitive : D
BCL2L1 overexpression	Acute Myelogenous Leukemia	BCL2L1 overexpression	Acute Myelogenous Leukemia	venetoclax + AZD5991 Sensitive: D – Preclinical venetoclax + AZD5991 Sensitive : D	venetoclax + AZD5991 Sensitive: D – Preclinical venetoclax + AZD5991 Sensitive : D
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	venetoclax + AZD5991 Sensitive: D – Preclinical venetoclax + AZD5991 Sensitive : D	venetoclax + AZD5991 Sensitive: D – Preclinical venetoclax + AZD5991 Sensitive : D
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	AZD5991 Resistant: D – Preclinical AZD5991 Resistant : D	AZD5991 Resistant: D – Preclinical AZD5991 Resistant : D